In a WHO 2021 cohort, the survival of GBM patients with or without MGMT promoter methylation was significantly different (p = 0.0001) with a mean survival of 478 days for patients with MGMT promoter methylated tumors versus 142 days for patients with MGMT promoter unmethylated tumors (Stoyanov et al., 2022). The gene discussed is MGMT; the disease is glioblastoma.